Yes, Rebif (interferon beta-1a) is administered as a subcutaneous injection.
How is Rebif given?
Patients self-inject Rebif under the skin, typically three times a week on alternate days. Doses are 22 mcg or 44 mcg per injection, using prefilled syringes or a reusable autoinjector like RebiSmart. Injection sites rotate among the abdomen, arms, hips, and thighs to minimize irritation.[1]
What devices are used for subcutaneous delivery?
Rebif comes in single-use prefilled syringes for manual injection or the RebiSmart electronic autoinjector, which simplifies the process with dose reminders and site selection guidance. Both deliver the drug subcutaneously.[1][2]
Why subcutaneous instead of other routes?
Subcutaneous administration provides steady absorption for this multiple sclerosis treatment, reducing injection-site reactions compared to intramuscular options like Avonex (another interferon beta-1a). Clinical trials confirmed efficacy with this route.[3]
Common side effects from subcutaneous injections
Flu-like symptoms (fever, chills, fatigue) occur in most patients shortly after injection, often managed with pain relievers. Local reactions like redness or pain at the site affect up to 60% initially but decrease over time.[1][4]
[1]: Rebif Prescribing Information (EMD Serono)
[2]: RebiSmart Device Guide
[3]: FDA Label for Rebif
[4]: Multiple Sclerosis Association of America on Interferons